Copyright
©The Author(s) 2021.
World J Stem Cells. Jan 26, 2021; 13(1): 64-77
Published online Jan 26, 2021. doi: 10.4252/wjsc.v13.i1.64
Published online Jan 26, 2021. doi: 10.4252/wjsc.v13.i1.64
Regeneration mechanisms | Cell types | Clinical/preclinical agents | Ref. |
Correction of glucotoxicity and lipotoxicity | All antidiabetic drugs | [16-18] | |
Suppression of the immune system | Immunomodulation therapies, for instance, activation of the nuclear receptor LRH-1/NR5A2, CD3 mAb, GABA, GLP-1 | [21-24] | |
Inhibition of cell death | Islet β cells | GLP-1, metformin, angiotensin-converting enzyme inhibitors | [25,27,28] |
Inhibition of cell dedifferentiation | Islet β cells | Antidiabetic drugs and the diabetes management, such as diet, exercise, or intensive insulin therapy; Other drugs, such as salsalate, renin–angiotensin system inhibitors | [35,36]; [37,38] |
Stimulation of cell proliferation | Islet β cells | A large number of growth factors and mitogenic agents, including hepatocyte growth factor, GLP-1, insulin-like growth factors, epidermal growth factors in rodent models; Inhibition of Dyrk1a, SerpinB1, GABA, GLP-1, etc.; Combining of the Dyrk1a inhibitor with the GLP-1 receptor agonist; combined inhibition of Dyrk1a, SMAD and Trithorax pathways | [42]; [48-51]; [52,53] |
Promotion of stem cell differentiation | Pluriopotent stem cells | Stepwise induction with cocktails of cytokines and chemicals; GLP-1, ascorbic acid, zinc sulfate, N-acetyl cysteine, etc. | [54-58]; [56,58,65-66] |
Stem cell-derived pancreatic endoderm cells or progenitors | GLP-1 | [67] | |
Mesenchymal stem cells | Stepwise induction | [63] | |
Pancreatic stem or progenitor cells in vivo | GLP-1, dipeptidyl peptidase 4 inhibitor, fasting-mimicking diet, etc. | [79-82] | |
Induction of cell transdifferentiation and transdetermination | Pancreatic α cells | GABA, artemisins, GLP-1, glucagon receptor mAb, sodium-glucose co-transporter type 2 inhibitor inhibitor, fibroblast growth factor 21, etc. | [87,88,90,91,93,94] |
Pancreatic δ-cells | FoxO1 inhibitor, etc. | [13] | |
Pancreatic acinar cells | Cytokine mixture of epidermal growth factor and ciliary neurotrophic factor | [98] | |
Enteroendocrine progenitors | FoxO1 inhibition, GLP-1, etc. | [100,104,105] | |
Other progenitors and mature cells, including hepatocytes, neuroendocrine cells | Not determined. |
- Citation: Wang KL, Tao M, Wei TJ, Wei R. Pancreatic β cell regeneration induced by clinical and preclinical agents. World J Stem Cells 2021; 13(1): 64-77
- URL: https://www.wjgnet.com/1948-0210/full/v13/i1/64.htm
- DOI: https://dx.doi.org/10.4252/wjsc.v13.i1.64